Rockefeller Capital Management
EVGN icon

Rockefeller Capital Management’s Evogene EVGN Stock Holding History

Rockefeller Capital Management’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,000
Closed -$12K – 1874
2023
Q1 		$12K Hold
2,000
– – ﹤0.01% 1951
2022
Q4 		$14K Buy
+2,000
New +$14.1K ﹤0.01% 2923

Other funds holding EVGN

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
JIC
Joel Isaacson & Co New York $3.02B AUM 21.81% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Rockefeller Capital Management's EVGN Position: Q2 2023 in Review

Rockefeller Capital Management sold out of Evogene (EVGN) in Q2 2023, closing a stake of 2,000 shares — an estimated $12K sold.

Rockefeller Capital Management first reported a position in EVGN in Q4 2022 and held it in 2 quarters. The position peaked at $14K in Q4 2022. 28 funds tracked by Wall St. Rank hold EVGN as of Q2 2023.

  • Rockefeller Capital Management reported no remaining Evogene position as of Q2 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 2,000 Evogene shares in Q2 2023, an estimated $12K.
  • Rockefeller Capital Management first reported a position in Evogene in Q4 2022 and held it in 2 quarters.
  • Rockefeller Capital Management's Evogene position peaked at $14K in Q4 2022.
  • 28 funds tracked by Wall St. Rank held Evogene as of Q2 2023.

Based on Rockefeller Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.